Home - DECISION

News

12.05.2023

DECISION in EASL Studio

DECISION members Pierre-Emmanuel Rautou and Paolo Caraceni have recently participated in two EASL Studio sessions, a weekly broadcast on news in hepatology and related fields.

Listen to Pierre-Emmanuel Rautou, coordinator of DECISION, in the EASL Studio Season 4, Episode 14 – EASL-EF CLIF and EU Grants: exploring novel mechanism and treatment of chronic liver failure

Additionally, tune in to Paolo Caraceni of UNIBO, contributing to Season 4, Episode 17 – Albumin in Cirrhosis: For All, For Some, For None.

More news

Events

21 - 24 June, 2023

DECISION at EASL Congress 2023

Meet DECISION members at the EASL Congress 2023 from 21 to 24 June in Vienna, Austria:

Thursday, 22. June 2023:

Pierre-Emmanuel and Virginia Hernandez-Gea (EASL) will chair the Research Think Tank: Vascular liver diseases beyond thrombosis (8:30-9:45 CET, room Lehar 4)
Sara Montagnese (UNIPD) will chair the Research Think Tank: Liver transplantation vs. alternative treatments in decompensated cirrhosis (8:30-9:45 CET, room Stolz 2)
Paolo Caraceni (UNIBO) will give a talk on “Preventing overt HE: long-term albumin as potential strategy” (12:45-13:45 CET)
Sophie Lotersztajn (INSERM) will host a State-of-the-art talk on "Stress response in Liver disease" (14:00-14:30 CET in the Auditorium)
There will be a roundtable on "The Future of Hepatology/Hepatologists: a mix of opportunities and threats" with Marko Korenjak (ELPA) from 15:00-16:00 CET, in room Lehar 3)
Pierre-Emmanuel will also give a talk titled "EVs, vectors of information between organs in liver diseases" (15:20-15:30, in room Lehar 1-2)

Friday, 23. June 2023:

Richard Moreau (INSERM): "The importance of scientific misconduct in peer- review" (8:30-9:30 CET, Workshop room)
Javier Fernández (FCRB): Hospitalised decompensated cirrhosis patients at high risk of infection – should we start empirical antibiotics or watch and wait for culture results (17:33-17:45 CET, Hepatology Arena)

Saturday, 24. June 2023:

Paolo Caraceni (UNIBO): “Systems medicine for identification of novel therapeutic strategies and biomarkers, insight from DECISION” (8:57-9:09 CET, Strauss 1 room)
Luis Téllez (SERMAS): The new diagnostic criteria of portopulmonary hypertension identify a group of patients with cirrhosis at high risk of death" (14:30-14:45 CET, Lehar 3)

More events

Twitter

Tweets by Decision4Liver

Our Vision

DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level by taking advantage of already existing large and clinically well characterized patient cohorts. The ultimate goal is to significantly reduce mortality through combinatorial therapies that are tailored to the specific needs of individual patients. Part of this endeavour is to develop a reliable prognostic test and a robust response test.

Learn more

Why it matters

In 2013, cirrhosis was responsible for 1.2 million deaths worldwide. While most cirrhosis patients initially do not show symptoms, acute decompensation of cirrhosis, defined as the body’s inability to cope with the progressing dysfunctionality of the liver, leads to drastic symptoms. Decompensation is characterized by the development of ascites, hepatic encephalopathy, jaundice, or gastrointestinal haemorrhage, and is often a turning point for cirrhosis.